Level Biotechnology (3118) - Total Liabilities
Based on the latest financial reports, Level Biotechnology (3118) has total liabilities worth NT$237.03 Million TWD (≈ $7.47 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Level Biotechnology - Total Liabilities Trend (2017–2024)
This chart illustrates how Level Biotechnology's total liabilities have evolved over time, based on quarterly financial data. See 3118 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Level Biotechnology Competitors by Total Liabilities
The table below lists competitors of Level Biotechnology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nordic Iron Ore
ST:NIO
|
Sweden | Skr17.16 Million |
|
Reino Capital SA
WAR:RNC
|
Poland | zł36.69 Million |
|
TeraGo Inc.
TO:TGO
|
Canada | CA$54.62 Million |
|
Auking Mining Ltd
AU:AKN
|
Australia | AU$1.81 Million |
|
Hankukpackage Co. Ltd
KQ:037230
|
Korea | ₩104.75 Billion |
|
Poulaillon SA
PA:ALPOU
|
France | €51.50 Million |
|
Fridenson
TA:FRDN
|
Israel | ILA185.56 Million |
|
Australian Mines Ltd
AU:AUZ
|
Australia | AU$207.00K |
Liability Composition Analysis (2017–2024)
This chart breaks down Level Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Level Biotechnology (3118) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Level Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Level Biotechnology (2017–2024)
The table below shows the annual total liabilities of Level Biotechnology from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$267.19 Million ≈ $8.42 Million |
-2.20% |
| 2023-12-31 | NT$273.20 Million ≈ $8.61 Million |
+1.14% |
| 2022-12-31 | NT$270.13 Million ≈ $8.51 Million |
+11.27% |
| 2021-12-31 | NT$242.78 Million ≈ $7.65 Million |
-0.32% |
| 2020-12-31 | NT$243.56 Million ≈ $7.67 Million |
+3.01% |
| 2019-12-31 | NT$236.43 Million ≈ $7.45 Million |
+30.19% |
| 2018-12-31 | NT$181.60 Million ≈ $5.72 Million |
-13.53% |
| 2017-12-31 | NT$210.03 Million ≈ $6.62 Million |
-- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more